Arcutis Biotherapeutics, Inc. (ARQT) Stock Grade

About Arcutis Biotherapeutics, Inc.'s fundamentals

Arcutis Biotherapeutics is a biotechnology company with a market capitalization of $3.7 billion that is experiencing significant revenue expansion, with year-over-year growth of 91.3%. However, the company is currently unprofitable, operating at a net margin of -4.3% and reporting a net loss in its latest annual statement. The company does not pay a dividend, which is typical for growth-stage biotech firms reinvesting capital into research and development. Without positive earnings, traditional valuation metrics like P/E ratio and return on equity are not applicable.